AlphaYou
Overview
8 funds hold it, insiders have been net selling, and 5 straight earnings beats.
Key stats
Sep 5- Open
- $1,150.61
- 52-wk high
- $1,292.65
- High
- $1,158.44
- 52-wk low
- $707.59
- Low
- $1,138.31
- Prev close
- $1,159.60
- Mkt cap
- $1.03T
- P/E
- 38.9x
- Volume
- 2.22M
- Fwd P/E
- 24.6x
- Beta
- 0.51
- Div yield
- 0.56%
- P/S
- 13.0x
- P/B
- 30.5x
- Profit margin
- +33.5%
- Op margin
- +54.2%
- ROE
- +102.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position, insiders have been net selling, and 2 fin-fluencers are discussing it.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 39.4% above what analysts expected.
Earnings per share
$6.01 expected
GAAP EPS was $7.94 and adjusted EPS was $8.38. The analyst basis could not be confirmed, so no beat or miss is shown.
FY2026 guidance
$85.00B to $87.00B
No comparable estimate
Reports Oct 29, 2026, in 54 days
EPS expected
$8.95 to $11.30
Revenue expected
14 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $17.60B | $19.29B | $19.80B | $22.97B |
| Cost of what it sold | $3.01B | $2.88B | $3.58B | $3.27B |
| Gross profit | $14.59B | $16.41B | $16.22B | $19.71B |
| What it spent | ||||
| Research and development | $3.47B | $3.80B | $3.51B | $3.82B |
| Sales and admin | $2.74B | $3.34B | $2.93B | $3.43B |
| Other operating costs | — | $487.5M | $928.0M | $3.48B |
| Total operating expenses | $6.21B | $7.63B | $7.37B | $10.73B |
| What was left | ||||
| Operating profit | $8.39B | $8.78B | $8.85B | $8.98B |
| Interest on debt | $179.6M | $123.0M | $332.0M | $345.0M |
| Profit before tax | $7.23B | $8.27B | $8.85B | $9.25B |
| Tax | $1.65B | $1.63B | $1.45B | $2.15B |
| Net profit | $5.58B | $6.64B | $7.40B | $7.09B |
| EBITDA | $7.88B | $8.39B | $9.69B | $9.25B |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Was JNJ Stock Rally Actually Its Own?
Leans bullishSep 4GSK wagers up to $1.3B on a different kind of cancer drug
NeutralSep 3Inventiva Completes NATiV3 Phase 3 Trial of Lanifibranor in MASH
NeutralSep 3Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
Leans bullishSep 2Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Leans bullishSep 2Novo Nordisk launches Wegovy weight-loss pill in Germany
NeutralSep 2Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
Leans bullishSep 1Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs
Leans bullishSep 1
Macro
30 macro signals shaping LLY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results